Cerus (CERS) Income from Continuing Operations (2010 - 2026)
Cerus (CERS) reported Income from Continuing Operations of 1648000.0 for Q1 2026, up 78.65% on a YoY basis from 922487.96 in Q1 2025, and up 24.54% sequentially from 2184000.0 in Q4 2025.
Cerus (CERS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cerus (CERS) has 17 years of Income from Continuing Operations data on file, last reported at 1648000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 78.65% year-over-year to 1648000.0; the trailing twelve-month figure through Mar 2026 stood at 9567000.0 (up 48.36% YoY), and the FY2025 full-year result was 15637000.0, up 23.71% from the prior year.
- Income from Continuing Operations improved to 1648000.0 in Q1 2026, from 2184000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 20000.0 in Q3 2025 to a low of 15641000.0 in Q1 2023.
- A 5-year average of 7000529.41 and a median of 7286000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 664.08% in 2022 and soared 99.32% in 2025, its largest moves.
- Tracing CERS's Income from Continuing Operations over 5 years: stood at 14384000.0 in 2022, then jumped by 90.37% to 1385000.0 in 2023, then slumped by 51.48% to 2098000.0 in 2024, then retreated by 4.1% to 2184000.0 in 2025, then rose by 24.54% to 1648000.0 in 2026.
- Business Quant data shows CERS's Income from Continuing Operations at 1648000.0 in Q1 2026, 2184000.0 in Q4 2025, and 20000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.71 Bn | 99.49 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.50 Bn | 67.05 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.59 Bn | 44.92 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 28.40 Bn | 27.29 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.37 Bn | 2.07 Bn | 273.95 Mn |
| 10 | Cerus | 602.81 Mn | 522.39 Mn | 27.89 Mn | -1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -7.72 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -5.78 Mn |
| Mar 31, 2024 | -9.69 Mn |
| Dec 31, 2023 | -1.39 Mn |
| Sep 30, 2023 | -7.29 Mn |
| Jun 30, 2023 | -13.33 Mn |
| Mar 31, 2023 | -15.64 Mn |
| Dec 31, 2022 | -14.38 Mn |
| Sep 30, 2022 | -8.52 Mn |
| Jun 30, 2022 | -8.40 Mn |
| Mar 31, 2022 | -12.28 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | -12.44 Mn |
| Jun 30, 2021 | -15.36 Mn |